tiprankstipranks
Bridgebio Pharma (BBIO)
NASDAQ:BBIO
US Market
BBIO
BridgeBio Pharma
RESEARCH TOOLSreports
Want to see BBIO full AI Analyst Report?

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

1,509 Followers
See the Price Targets and Ratings of:

BBIO Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
BridgeBio
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$108.29
▲(28.88% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $108.29 with a high forecast of $157.00 and a low forecast of $93.00. The average price target represents a 28.88% change from the last price of $84.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","74":"$74","102":"$102","130":"$130","158":"$158"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.28571428571426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$108.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$93.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,74,102,130,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.09,86.00615384615385,91.9223076923077,97.83846153846154,103.75461538461539,109.67076923076924,115.58692307692309,121.50307692307692,127.41923076923078,133.3353846153846,139.25153846153847,145.1676923076923,151.08384615384614,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.09,82.2589010989011,84.4278021978022,86.5967032967033,88.76560439560438,90.93450549450549,93.10340659340659,95.27230769230768,97.44120879120878,99.61010989010987,101.77901098901097,103.94791208791207,106.11681318681318,{"y":108.28571428571426,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.09,81.08307692307693,82.07615384615384,83.06923076923077,84.0623076923077,85.05538461538461,86.04846153846154,87.04153846153847,88.03461538461539,89.0276923076923,90.02076923076923,91.01384615384616,92.00692307692307,{"y":93,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.09,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$157.00Average Price Target$108.29Lowest Price Target$93.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$95→$110
Buy
30.92%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Rocket Pharmaceuticals (NASDAQ: RCKT)
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/11/26
BridgeBio Earns Buy Rating on Attruby Outperformance and Multibillion-Dollar Growth Visibility
Wells Fargo Analyst forecast on BBIO
Derek Archila
Wells Fargo
Wells Fargo
$98→$102
Buy
21.40%
Upside
Reiterated
08/11/26
Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Jefferies Analyst forecast on BBIO
Andrew Tsai
Jefferies
Jefferies
$100→$110
Buy
30.92%
Upside
Reiterated
08/11/26
Jefferies Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Morgan Stanley Analyst forecast on BBIO
Sean Laaman
Morgan Stanley
Morgan Stanley
$98→$97
Buy
15.45%
Upside
Assigned
08/11/26
BridgeBio price target lowered to $97 from $98 at Morgan StanleyBridgeBio price target lowered to $97 from $98 at Morgan Stanley
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$104
Buy
23.78%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (NASDAQ: BBIO), Hims & Hers Health (NYSE: HIMS) and Definitive Healthcare Corp (NASDAQ: DH)
Truist Financial Analyst forecast on BBIO
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$111→$115
Buy
36.87%
Upside
Assigned
08/11/26
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
J.P. Morgan Analyst forecast on BBIO
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Cantor Fitzgerald Analyst forecast on BBIO
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$110
Buy
30.92%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (NASDAQ: RPRX), BridgeBio Pharma (NASDAQ: BBIO) and NanoViricides (NYSE MKT: NNVC)
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
19.02%
Upside
Reiterated
08/10/26
RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$120
Buy
42.82%
Upside
Reiterated
07/24/26
Analyst Reiterates Buy on BridgeBio, Maintaining $120 Price Target as Late-Stage Rare Disease Pipeline Advances
Citi Analyst forecast on BBIO
Eric Joseph
Citi
Citi
$82→$93
Hold
10.69%
Upside
Assigned
07/17/26
BridgeBio price target raised to $93 from $82 at CitiBridgeBio price target raised to $93 from $82 at Citi
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157
Buy
86.86%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD), Teva Pharmaceutical (NYSE: TEVA) and BridgeBio Pharma (NASDAQ: BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim Syed
Mizuho Securities
Mizuho Securities
$96
Buy
14.26%
Upside
Reiterated
06/21/26
BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$95→$110
Buy
30.92%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Rocket Pharmaceuticals (NASDAQ: RCKT)
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/11/26
BridgeBio Earns Buy Rating on Attruby Outperformance and Multibillion-Dollar Growth Visibility
Wells Fargo Analyst forecast on BBIO
Derek Archila
Wells Fargo
Wells Fargo
$98→$102
Buy
21.40%
Upside
Reiterated
08/11/26
Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
Jefferies Analyst forecast on BBIO
Andrew Tsai
Jefferies
Jefferies
$100→$110
Buy
30.92%
Upside
Reiterated
08/11/26
Jefferies Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Morgan Stanley Analyst forecast on BBIO
Sean Laaman
Morgan Stanley
Morgan Stanley
$98→$97
Buy
15.45%
Upside
Assigned
08/11/26
BridgeBio price target lowered to $97 from $98 at Morgan StanleyBridgeBio price target lowered to $97 from $98 at Morgan Stanley
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$104
Buy
23.78%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (NASDAQ: BBIO), Hims & Hers Health (NYSE: HIMS) and Definitive Healthcare Corp (NASDAQ: DH)
Truist Financial Analyst forecast on BBIO
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$111→$115
Buy
36.87%
Upside
Assigned
08/11/26
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
J.P. Morgan Analyst forecast on BBIO
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Cantor Fitzgerald Analyst forecast on BBIO
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$110
Buy
30.92%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (NASDAQ: RPRX), BridgeBio Pharma (NASDAQ: BBIO) and NanoViricides (NYSE MKT: NNVC)
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
19.02%
Upside
Reiterated
08/10/26
RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$120
Buy
42.82%
Upside
Reiterated
07/24/26
Analyst Reiterates Buy on BridgeBio, Maintaining $120 Price Target as Late-Stage Rare Disease Pipeline Advances
Citi Analyst forecast on BBIO
Eric Joseph
Citi
Citi
$82→$93
Hold
10.69%
Upside
Assigned
07/17/26
BridgeBio price target raised to $93 from $82 at CitiBridgeBio price target raised to $93 from $82 at Citi
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157
Buy
86.86%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD), Teva Pharmaceutical (NYSE: TEVA) and BridgeBio Pharma (NASDAQ: BBIO)
Mizuho Securities Analyst forecast on BBIO
Salim Syed
Mizuho Securities
Mizuho Securities
$96
Buy
14.26%
Upside
Reiterated
06/21/26
BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months
Cory KasimovEvercore ISI
Success Rate
12/16 ratings generated profit
75%
Average Return
+15.12%
Copying Cory Kasimov's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.12% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
16/16 ratings generated profit
100%
Average Return
+82.36%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +82.36% per trade.
2 Years
Cory KasimovEvercore ISI
Success Rate
16/16 ratings generated profit
100%
Average Return
+139.34%
Copying Cory Kasimov's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +139.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
16
18
18
14
4
Buy
36
26
21
23
26
Hold
0
4
5
6
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
52
48
44
43
32
In the current month, BBIO has received 30 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 108.29.
Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.60 with a range of -$0.87 to -$0.25. The previous quarter’s EPS was -$0.78. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s earnings estimate for BBIO is -$0.60 with a range of -$0.87 to -$0.25. The previous quarter’s EPS was -$0.78. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $262.77M with a range of $242.35M to $285.20M. The previous quarter’s sales results were $243.68M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s sales forecast for BBIO is $262.77M with a range of $242.35M to $285.20M. The previous quarter’s sales results were $243.68M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Bridgebio Pharma’s 12-month average price target is 108.29.
    What is BBIO’s upside potential, based on the analysts’ average price target?
    Bridgebio Pharma has 28.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBIO a Buy, Sell or Hold?
          Bridgebio Pharma has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Bridgebio Pharma’s price target?
            The average price target for Bridgebio Pharma is 108.29. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $157.00 ,the lowest forecast is $93.00. The average price target represents 28.88% Increase from the current price of $84.02.
              What do analysts say about Bridgebio Pharma?
              Bridgebio Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of BBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.